AI
Monday, February 09, 2026 7:20:03 AM
I come bearing good news. So after the publishing of the National Cancer Plan it was clear to me that almost the entire plan's applicability to NWBO and DCVax rested on whether or not DCVax would be eligible to join the NHS's Cancer Vaccine Launch Pad (CVLP).
If you remember, back in May last year I emailed the CVLP to ask “whether the scope of the CVLP will be expanded in due course to include dendritic cell vaccines instead of its present focus on just mRNA based vaccines?”, this was their answer in August:
“Thank you for your email regarding the NHS Cancer Vaccines Launch Pad (CVLP). The NHS Cancer Vaccine Launchpad (CVLP) is a platform facilitating access to clinical trials of cancer vaccine treatment where the cancer vaccines are created by analysing a patient’s tumour and identifying specific mutations that are unique to that cancer, then using that information to create a vaccine tailored to the patient.
The NHS CVLP was designed with lessons learnt by the NHS in delivering coronavirus vaccine studies. The platform is being built to be agnostic to the commercial company and clinical trials while ensuring it is patient-focussed with equity of access.
The scope of the Cancer Vaccine Launch Pad (CVLP) has now been expanded to include cancer immunotherapies and cancer vaccines or other personalised immunotherapy that require molecular profiling or genetic sequencing.”
Although promising on the face of it, I found this answer a little difficult to interpret due to the Oxford comma conundrum. Did they mean that the CVLP had been expanded to include cancer immunotherapies and cancer vaccines or other personalised immunotherapy all of which that specifically and only require molecular profiling or genetic sequencing as part of the treatment process, or, did they mean that the CVLP had been expanded to include:
i) cancer immunotherapies
ii) cancer vaccines
iii) other personalised immunotherapy that require molecular profiling or genetic sequencing
It’s a subtle contrast, but it makes ALL the difference as to whether DCVax would fall under the CVLP umbrella or not.
Having read the National Cancer Plan and seeing how much of the Plan hinged around the CVLP it actually made me quite uncomfortable to consider that if read the first way - written without any commas - there was the potential for the National Cancer Plan to in fact be completely snubbing Dendritic Cell Therapies/ NWBO and concentrating entirely on mRHA and CAR-T. So, I wrote back to the CVLP and asked them:
"Dear CVLP Team,
Thank you for your previous reply regarding the scope of the CVLP.
I am writing to seek specific technical clarification on the definition you provided: "cancer immunotherapies and cancer vaccines or other personalised immunotherapy that require molecular profiling or genetic sequencing."
There is some ambiguity in whether the requirement for "molecular profiling/genetic sequencing" applies to all categories in that list, or solely to the "other" category.
Specifically, I am asking if the CVLP infrastructure allows for the inclusion of autologous whole-tumour lysate dendritic cell vaccines.
As you are aware, this class of treatment (unlike mRNA or peptide vaccines) is biomarker-agnostic and polyclonal. It relies on the patient’s physical tumour tissue (lysate) rather than a digital genomic sequence to manufacture. Therefore, it does not require the specific genomic profiling workflow currently used for BioNTech/Moderna trials.
Could you please confirm strictly:
1. Is the CVLP technically capable of onboarding a trial for a therapy that does not utilize a genomic sequence for manufacturing (i.e., a tissue-based lysate vaccine)?
2. Does the "expanded scope" you mentioned explicitly exclude treatments that are effectively "ready" (Phase 3 data available) but awaiting regulatory/funding clearance, such as DCVax-L?
Given the government’s recent announcement regarding "Greater access to breakthrough trials," it is vital for patients to understand if the CVLP is exclusively a genomic-match engine, or if it is truly open to all forms of personalised immunotherapy.
I look forward to your specific guidance on this technical distinction."
And this morning I already received a reply from them, thankfully about 3 months quicker than the last time I emailed (see attached).
So with this in mind it is clear that the UK National Cancer Plan is also very much geared towards DCVax. I believe this means the following:
1. Immediate Access to the National Cancer Plan via the CVLP. The CVLP is the central mechanism in the National Cancer Plan for fast-tracking cancer vaccines, which means DCVax-L (or future iterations like DCVax-Direct) can utilise the CVLP infrastructure. This infrastructure includes patient identification (finding eligible patients via NHS data) and referral networks (sending them to trial sites). The plan effectively offers NWBO a government-funded recruitment engine.
2. Molecular Profiling is an eligibility tool, not a barrier. The email clarifies that molecular profiling is used for eligibility or stratification, not just manufacturing. Even though DCVax-L is biomarker agnostic (works for everyone), the CVLP can still use profiling to monitor patients. For example, they can use the CVLP's genomic testing to track how well DCVax-L works in patients with specific mutations (like IDH-wildtype vs mutant). This turns the genomic focus of the plan from a barrier into a validation tool for NWBO.
3. Funding for infrastructure should benefit Advent Bioservices. The Plan commits to investing in "aseptic medicines production hubs" (Action 8) and reducing setup times for trials. Since DCVax-L is now confirmed to be in the CVLP remit, the government’s push to build infrastructure for "personalised immunotherapies" directly supports the logistics NWBO needs. The hiring at Advent Bioservices (Grade C suites, admin coordinators) aligns perfectly with a facility preparing to plug into this national network.
4. The Rare Cancers Fast-Track (Action 13). The confirmation that DCVax is entirely eligible for the CVLP strengthens the link to the Rare Cancers Bill, which is being read in Parliament in 2 days. The Plan explicitly says it will "implement the Rare Cancers Bill" and "review market authorisations." Now that we know the NHS will include lysate vaccines in their Launch Pad, the MAA is far more likely to be favourable, particularly when keeping in mind the existing DCVax NHS IFR list inclusion.
5. Commercial & Trial Implications. The email invited me to "discuss the potential for the CVLP to support a specific clinical trial." This looks like an open door for NWBO to run a Phase 4 (Post-Approval) trial or a combo therapy trial through the CVLP. If the MHRA was to grant NWBO a Conditional Approval (requiring more data), NWBO can now seemingly use the CVLP to gather that data. This removes the massive cost and logistical burden of running a post-market registry independently.
The National Cancer Plan is no longer seemingly just a brochure for mRNA. It is a funded infrastructure project that has just explicitly just confirmed that it will include autologous whole-tumour lysate dendritic cell vaccines.
The National Cancer Plan doesn't name dendritic cell vaccines or DCVax because it's a policy document and DCVax is so far yet to be approved, but the category “immunotherapies with molecular profiling elements" has now been officially widened to include it.
It seems that the combination of the imminent MHRA decision + confirmed potential for DCVax's CVLP inclusion + Advent’s readiness creates a complete commercial ecosystem for DCVax-L in the UK supported by the UK's new National Cancer Plan. We are now looking at a potential scenario where the UK government could effectively become NWBO's funding partner to help roll out DCVax to UK patients and help fund further trials, and I don't believe I am exaggerating by saying this.
GLTA
If you remember, back in May last year I emailed the CVLP to ask “whether the scope of the CVLP will be expanded in due course to include dendritic cell vaccines instead of its present focus on just mRNA based vaccines?”, this was their answer in August:
“Thank you for your email regarding the NHS Cancer Vaccines Launch Pad (CVLP). The NHS Cancer Vaccine Launchpad (CVLP) is a platform facilitating access to clinical trials of cancer vaccine treatment where the cancer vaccines are created by analysing a patient’s tumour and identifying specific mutations that are unique to that cancer, then using that information to create a vaccine tailored to the patient.
The NHS CVLP was designed with lessons learnt by the NHS in delivering coronavirus vaccine studies. The platform is being built to be agnostic to the commercial company and clinical trials while ensuring it is patient-focussed with equity of access.
The scope of the Cancer Vaccine Launch Pad (CVLP) has now been expanded to include cancer immunotherapies and cancer vaccines or other personalised immunotherapy that require molecular profiling or genetic sequencing.”
Although promising on the face of it, I found this answer a little difficult to interpret due to the Oxford comma conundrum. Did they mean that the CVLP had been expanded to include cancer immunotherapies and cancer vaccines or other personalised immunotherapy all of which that specifically and only require molecular profiling or genetic sequencing as part of the treatment process, or, did they mean that the CVLP had been expanded to include:
i) cancer immunotherapies
ii) cancer vaccines
iii) other personalised immunotherapy that require molecular profiling or genetic sequencing
It’s a subtle contrast, but it makes ALL the difference as to whether DCVax would fall under the CVLP umbrella or not.
Having read the National Cancer Plan and seeing how much of the Plan hinged around the CVLP it actually made me quite uncomfortable to consider that if read the first way - written without any commas - there was the potential for the National Cancer Plan to in fact be completely snubbing Dendritic Cell Therapies/ NWBO and concentrating entirely on mRHA and CAR-T. So, I wrote back to the CVLP and asked them:
"Dear CVLP Team,
Thank you for your previous reply regarding the scope of the CVLP.
I am writing to seek specific technical clarification on the definition you provided: "cancer immunotherapies and cancer vaccines or other personalised immunotherapy that require molecular profiling or genetic sequencing."
There is some ambiguity in whether the requirement for "molecular profiling/genetic sequencing" applies to all categories in that list, or solely to the "other" category.
Specifically, I am asking if the CVLP infrastructure allows for the inclusion of autologous whole-tumour lysate dendritic cell vaccines.
As you are aware, this class of treatment (unlike mRNA or peptide vaccines) is biomarker-agnostic and polyclonal. It relies on the patient’s physical tumour tissue (lysate) rather than a digital genomic sequence to manufacture. Therefore, it does not require the specific genomic profiling workflow currently used for BioNTech/Moderna trials.
Could you please confirm strictly:
1. Is the CVLP technically capable of onboarding a trial for a therapy that does not utilize a genomic sequence for manufacturing (i.e., a tissue-based lysate vaccine)?
2. Does the "expanded scope" you mentioned explicitly exclude treatments that are effectively "ready" (Phase 3 data available) but awaiting regulatory/funding clearance, such as DCVax-L?
Given the government’s recent announcement regarding "Greater access to breakthrough trials," it is vital for patients to understand if the CVLP is exclusively a genomic-match engine, or if it is truly open to all forms of personalised immunotherapy.
I look forward to your specific guidance on this technical distinction."
And this morning I already received a reply from them, thankfully about 3 months quicker than the last time I emailed (see attached).
So with this in mind it is clear that the UK National Cancer Plan is also very much geared towards DCVax. I believe this means the following:
1. Immediate Access to the National Cancer Plan via the CVLP. The CVLP is the central mechanism in the National Cancer Plan for fast-tracking cancer vaccines, which means DCVax-L (or future iterations like DCVax-Direct) can utilise the CVLP infrastructure. This infrastructure includes patient identification (finding eligible patients via NHS data) and referral networks (sending them to trial sites). The plan effectively offers NWBO a government-funded recruitment engine.
2. Molecular Profiling is an eligibility tool, not a barrier. The email clarifies that molecular profiling is used for eligibility or stratification, not just manufacturing. Even though DCVax-L is biomarker agnostic (works for everyone), the CVLP can still use profiling to monitor patients. For example, they can use the CVLP's genomic testing to track how well DCVax-L works in patients with specific mutations (like IDH-wildtype vs mutant). This turns the genomic focus of the plan from a barrier into a validation tool for NWBO.
3. Funding for infrastructure should benefit Advent Bioservices. The Plan commits to investing in "aseptic medicines production hubs" (Action 8) and reducing setup times for trials. Since DCVax-L is now confirmed to be in the CVLP remit, the government’s push to build infrastructure for "personalised immunotherapies" directly supports the logistics NWBO needs. The hiring at Advent Bioservices (Grade C suites, admin coordinators) aligns perfectly with a facility preparing to plug into this national network.
4. The Rare Cancers Fast-Track (Action 13). The confirmation that DCVax is entirely eligible for the CVLP strengthens the link to the Rare Cancers Bill, which is being read in Parliament in 2 days. The Plan explicitly says it will "implement the Rare Cancers Bill" and "review market authorisations." Now that we know the NHS will include lysate vaccines in their Launch Pad, the MAA is far more likely to be favourable, particularly when keeping in mind the existing DCVax NHS IFR list inclusion.
5. Commercial & Trial Implications. The email invited me to "discuss the potential for the CVLP to support a specific clinical trial." This looks like an open door for NWBO to run a Phase 4 (Post-Approval) trial or a combo therapy trial through the CVLP. If the MHRA was to grant NWBO a Conditional Approval (requiring more data), NWBO can now seemingly use the CVLP to gather that data. This removes the massive cost and logistical burden of running a post-market registry independently.
The National Cancer Plan is no longer seemingly just a brochure for mRNA. It is a funded infrastructure project that has just explicitly just confirmed that it will include autologous whole-tumour lysate dendritic cell vaccines.
The National Cancer Plan doesn't name dendritic cell vaccines or DCVax because it's a policy document and DCVax is so far yet to be approved, but the category “immunotherapies with molecular profiling elements" has now been officially widened to include it.
It seems that the combination of the imminent MHRA decision + confirmed potential for DCVax's CVLP inclusion + Advent’s readiness creates a complete commercial ecosystem for DCVax-L in the UK supported by the UK's new National Cancer Plan. We are now looking at a potential scenario where the UK government could effectively become NWBO's funding partner to help roll out DCVax to UK patients and help fund further trials, and I don't believe I am exaggerating by saying this.
GLTA
Bullish
